Study details
Enrolling now
A Study of Isoquercetin in People With Ovarian Cancer
Memorial Sloan Kettering Cancer Center
NCT IDNCT07303894ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
90
Study length
about 6 years
Ages
18+
Locations
8 sites in MA, NJ, NY
What this study is about
This trial is testing whether isoquercetin can reduce markers in the blood that may indicate the risk of blood clots in people with ovarian cancer. The effects of isoquercetin will be compared with those of a placebo.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Placebo
- 2.Take Isoquercetin
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Body systems
Oncology